Loading…

Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats

BACKGROUND Glucagon-like peptide-1 (GLP-1) has been reported to exert some beneficial effects on the central nervous system (CNS). However, the effect of GLP-1 on cognitive impairment associated with type 2 diabetes is not well known. This study investigated the effect of GLP-1 on ameliorating memor...

Full description

Saved in:
Bibliographic Details
Published in:Medical science monitor 2017-09, Vol.23, p.4334-4342
Main Authors: Cai, Xiang-Sheng, Tan, Zhao-Guang, Li, Jing-Jing, Gao, Wei-Hong, Li, Shu-Ji, Li, Jin-Long, Tang, Yong-Ming, Li, Hong-Wei, Hui, Hong-Xiang
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2962-6a90a60b75f8925c46768cf1396380f4fd8f38c18b8ffccfe64c7afded34f9333
cites
container_end_page 4342
container_issue
container_start_page 4334
container_title Medical science monitor
container_volume 23
creator Cai, Xiang-Sheng
Tan, Zhao-Guang
Li, Jing-Jing
Gao, Wei-Hong
Li, Shu-Ji
Li, Jin-Long
Tang, Yong-Ming
Li, Hong-Wei
Hui, Hong-Xiang
description BACKGROUND Glucagon-like peptide-1 (GLP-1) has been reported to exert some beneficial effects on the central nervous system (CNS). However, the effect of GLP-1 on cognitive impairment associated with type 2 diabetes is not well known. This study investigated the effect of GLP-1 on ameliorating memory deficits in type 2 diabetic rats. MATERIAL AND METHODS Type 2 diabetic rats were induced by a high-sugar, high-fat diet, followed by streptozotocin (STZ) injection and then tested in the Morris Water Maze (MWM) 1 week after the induction of diabetes. The mRNA expression of Arc, APP, BACE1, and PS1 were determined by real-time quantitative PCR, and the Arc protein was analyzed by immunoblotting and immunohistochemistry. RESULTS Type 2 diabetic rats exhibited a significant decline in learning and memory in the MWM tests, but GLP-1 treatment was able to protect this decline and significantly improved learning ability and memory. The mRNA expression assays showed that GLP-1 treatment markedly reduced Arc, APP, BACE1, and PS1 expressions, which were elevated in the diabetic rats. Immunoblotting and immunohistochemistry results also confirmed that Arc protein increased in the hippocampus of diabetic rats, but was reduced after GLP-1 treatment. CONCLUSIONS Our findings suggest that GLP-1 treatment improves learning and memory deficits in type 2 diabetic rats, and this effect is likely through the reduction of Arc expression in the hippocampus.
doi_str_mv 10.12659/MSM.903252
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5601394</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1937528807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2962-6a90a60b75f8925c46768cf1396380f4fd8f38c18b8ffccfe64c7afded34f9333</originalsourceid><addsrcrecordid>eNpVkc1v1DAQxS1ERT_gxB35WIRSHDt27AvSainbSltRwXK2HGe8GBIntZ2KvfVPJ-q2VXuakean90bvIfS-JGclFVx9vvp5daYIo5y-QkelqFjBak5eP9sP0XFKfwihUhD-Bh1SKSVXih-hu1U3WbMdQrH2fwFfw5h9C0WJT1fr66L8iDcRTO4hZLzoofNDNBkSXg7b4LO_BXzZj8bHe6DZ4UXOECaTfdjiRbT4_N8YISU_BOwD3uxGwBR_9aaB7C3-YXJ6iw6c6RK8e5gn6Ne3883yolh_X10uF-vCUiVoIYwiRpCm5k4qym0laiGtK5kSTBJXuVY6Jm0pG-mctQ5EZWvjWmhZ5RRj7AR92euOU9NDa-eHo-n0GH1v4k4PxuuXl-B_6-1wq7kgs0s1C5w-CMThZoKUde-Tha4zAYYp6VLNSc_BknpGP-1RG4eUIrgnm5Lo-8703JnedzbTH55_9sQ-lsT-AxnTkxU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1937528807</pqid></control><display><type>article</type><title>Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats</title><source>PMC (PubMed Central)</source><creator>Cai, Xiang-Sheng ; Tan, Zhao-Guang ; Li, Jing-Jing ; Gao, Wei-Hong ; Li, Shu-Ji ; Li, Jin-Long ; Tang, Yong-Ming ; Li, Hong-Wei ; Hui, Hong-Xiang</creator><creatorcontrib>Cai, Xiang-Sheng ; Tan, Zhao-Guang ; Li, Jing-Jing ; Gao, Wei-Hong ; Li, Shu-Ji ; Li, Jin-Long ; Tang, Yong-Ming ; Li, Hong-Wei ; Hui, Hong-Xiang</creatorcontrib><description>BACKGROUND Glucagon-like peptide-1 (GLP-1) has been reported to exert some beneficial effects on the central nervous system (CNS). However, the effect of GLP-1 on cognitive impairment associated with type 2 diabetes is not well known. This study investigated the effect of GLP-1 on ameliorating memory deficits in type 2 diabetic rats. MATERIAL AND METHODS Type 2 diabetic rats were induced by a high-sugar, high-fat diet, followed by streptozotocin (STZ) injection and then tested in the Morris Water Maze (MWM) 1 week after the induction of diabetes. The mRNA expression of Arc, APP, BACE1, and PS1 were determined by real-time quantitative PCR, and the Arc protein was analyzed by immunoblotting and immunohistochemistry. RESULTS Type 2 diabetic rats exhibited a significant decline in learning and memory in the MWM tests, but GLP-1 treatment was able to protect this decline and significantly improved learning ability and memory. The mRNA expression assays showed that GLP-1 treatment markedly reduced Arc, APP, BACE1, and PS1 expressions, which were elevated in the diabetic rats. Immunoblotting and immunohistochemistry results also confirmed that Arc protein increased in the hippocampus of diabetic rats, but was reduced after GLP-1 treatment. CONCLUSIONS Our findings suggest that GLP-1 treatment improves learning and memory deficits in type 2 diabetic rats, and this effect is likely through the reduction of Arc expression in the hippocampus.</description><identifier>ISSN: 1643-3750</identifier><identifier>ISSN: 1234-1010</identifier><identifier>EISSN: 1643-3750</identifier><identifier>DOI: 10.12659/MSM.903252</identifier><identifier>PMID: 28885995</identifier><language>eng</language><publisher>United States: International Scientific Literature, Inc</publisher><subject>Animal Study ; Animals ; Blood Glucose - metabolism ; Cognitive Dysfunction - blood ; Cognitive Dysfunction - drug therapy ; Cognitive Dysfunction - metabolism ; Cytoskeletal Proteins - metabolism ; Diabetes Mellitus, Experimental - metabolism ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Diet, High-Fat - adverse effects ; Disease Models, Animal ; Glucagon-Like Peptide 1 - pharmacology ; Hippocampus - drug effects ; Male ; Maze Learning - drug effects ; Memory Disorders - complications ; Nerve Tissue Proteins - metabolism ; Rats ; Rats, Sprague-Dawley</subject><ispartof>Medical science monitor, 2017-09, Vol.23, p.4334-4342</ispartof><rights>Med Sci Monit, 2017 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2962-6a90a60b75f8925c46768cf1396380f4fd8f38c18b8ffccfe64c7afded34f9333</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601394/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601394/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28885995$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cai, Xiang-Sheng</creatorcontrib><creatorcontrib>Tan, Zhao-Guang</creatorcontrib><creatorcontrib>Li, Jing-Jing</creatorcontrib><creatorcontrib>Gao, Wei-Hong</creatorcontrib><creatorcontrib>Li, Shu-Ji</creatorcontrib><creatorcontrib>Li, Jin-Long</creatorcontrib><creatorcontrib>Tang, Yong-Ming</creatorcontrib><creatorcontrib>Li, Hong-Wei</creatorcontrib><creatorcontrib>Hui, Hong-Xiang</creatorcontrib><title>Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats</title><title>Medical science monitor</title><addtitle>Med Sci Monit</addtitle><description>BACKGROUND Glucagon-like peptide-1 (GLP-1) has been reported to exert some beneficial effects on the central nervous system (CNS). However, the effect of GLP-1 on cognitive impairment associated with type 2 diabetes is not well known. This study investigated the effect of GLP-1 on ameliorating memory deficits in type 2 diabetic rats. MATERIAL AND METHODS Type 2 diabetic rats were induced by a high-sugar, high-fat diet, followed by streptozotocin (STZ) injection and then tested in the Morris Water Maze (MWM) 1 week after the induction of diabetes. The mRNA expression of Arc, APP, BACE1, and PS1 were determined by real-time quantitative PCR, and the Arc protein was analyzed by immunoblotting and immunohistochemistry. RESULTS Type 2 diabetic rats exhibited a significant decline in learning and memory in the MWM tests, but GLP-1 treatment was able to protect this decline and significantly improved learning ability and memory. The mRNA expression assays showed that GLP-1 treatment markedly reduced Arc, APP, BACE1, and PS1 expressions, which were elevated in the diabetic rats. Immunoblotting and immunohistochemistry results also confirmed that Arc protein increased in the hippocampus of diabetic rats, but was reduced after GLP-1 treatment. CONCLUSIONS Our findings suggest that GLP-1 treatment improves learning and memory deficits in type 2 diabetic rats, and this effect is likely through the reduction of Arc expression in the hippocampus.</description><subject>Animal Study</subject><subject>Animals</subject><subject>Blood Glucose - metabolism</subject><subject>Cognitive Dysfunction - blood</subject><subject>Cognitive Dysfunction - drug therapy</subject><subject>Cognitive Dysfunction - metabolism</subject><subject>Cytoskeletal Proteins - metabolism</subject><subject>Diabetes Mellitus, Experimental - metabolism</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diet, High-Fat - adverse effects</subject><subject>Disease Models, Animal</subject><subject>Glucagon-Like Peptide 1 - pharmacology</subject><subject>Hippocampus - drug effects</subject><subject>Male</subject><subject>Maze Learning - drug effects</subject><subject>Memory Disorders - complications</subject><subject>Nerve Tissue Proteins - metabolism</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><issn>1643-3750</issn><issn>1234-1010</issn><issn>1643-3750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVkc1v1DAQxS1ERT_gxB35WIRSHDt27AvSainbSltRwXK2HGe8GBIntZ2KvfVPJ-q2VXuakean90bvIfS-JGclFVx9vvp5daYIo5y-QkelqFjBak5eP9sP0XFKfwihUhD-Bh1SKSVXih-hu1U3WbMdQrH2fwFfw5h9C0WJT1fr66L8iDcRTO4hZLzoofNDNBkSXg7b4LO_BXzZj8bHe6DZ4UXOECaTfdjiRbT4_N8YISU_BOwD3uxGwBR_9aaB7C3-YXJ6iw6c6RK8e5gn6Ne3883yolh_X10uF-vCUiVoIYwiRpCm5k4qym0laiGtK5kSTBJXuVY6Jm0pG-mctQ5EZWvjWmhZ5RRj7AR92euOU9NDa-eHo-n0GH1v4k4PxuuXl-B_6-1wq7kgs0s1C5w-CMThZoKUde-Tha4zAYYp6VLNSc_BknpGP-1RG4eUIrgnm5Lo-8703JnedzbTH55_9sQ-lsT-AxnTkxU</recordid><startdate>20170908</startdate><enddate>20170908</enddate><creator>Cai, Xiang-Sheng</creator><creator>Tan, Zhao-Guang</creator><creator>Li, Jing-Jing</creator><creator>Gao, Wei-Hong</creator><creator>Li, Shu-Ji</creator><creator>Li, Jin-Long</creator><creator>Tang, Yong-Ming</creator><creator>Li, Hong-Wei</creator><creator>Hui, Hong-Xiang</creator><general>International Scientific Literature, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170908</creationdate><title>Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats</title><author>Cai, Xiang-Sheng ; Tan, Zhao-Guang ; Li, Jing-Jing ; Gao, Wei-Hong ; Li, Shu-Ji ; Li, Jin-Long ; Tang, Yong-Ming ; Li, Hong-Wei ; Hui, Hong-Xiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2962-6a90a60b75f8925c46768cf1396380f4fd8f38c18b8ffccfe64c7afded34f9333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animal Study</topic><topic>Animals</topic><topic>Blood Glucose - metabolism</topic><topic>Cognitive Dysfunction - blood</topic><topic>Cognitive Dysfunction - drug therapy</topic><topic>Cognitive Dysfunction - metabolism</topic><topic>Cytoskeletal Proteins - metabolism</topic><topic>Diabetes Mellitus, Experimental - metabolism</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diet, High-Fat - adverse effects</topic><topic>Disease Models, Animal</topic><topic>Glucagon-Like Peptide 1 - pharmacology</topic><topic>Hippocampus - drug effects</topic><topic>Male</topic><topic>Maze Learning - drug effects</topic><topic>Memory Disorders - complications</topic><topic>Nerve Tissue Proteins - metabolism</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><toplevel>online_resources</toplevel><creatorcontrib>Cai, Xiang-Sheng</creatorcontrib><creatorcontrib>Tan, Zhao-Guang</creatorcontrib><creatorcontrib>Li, Jing-Jing</creatorcontrib><creatorcontrib>Gao, Wei-Hong</creatorcontrib><creatorcontrib>Li, Shu-Ji</creatorcontrib><creatorcontrib>Li, Jin-Long</creatorcontrib><creatorcontrib>Tang, Yong-Ming</creatorcontrib><creatorcontrib>Li, Hong-Wei</creatorcontrib><creatorcontrib>Hui, Hong-Xiang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical science monitor</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cai, Xiang-Sheng</au><au>Tan, Zhao-Guang</au><au>Li, Jing-Jing</au><au>Gao, Wei-Hong</au><au>Li, Shu-Ji</au><au>Li, Jin-Long</au><au>Tang, Yong-Ming</au><au>Li, Hong-Wei</au><au>Hui, Hong-Xiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats</atitle><jtitle>Medical science monitor</jtitle><addtitle>Med Sci Monit</addtitle><date>2017-09-08</date><risdate>2017</risdate><volume>23</volume><spage>4334</spage><epage>4342</epage><pages>4334-4342</pages><issn>1643-3750</issn><issn>1234-1010</issn><eissn>1643-3750</eissn><abstract>BACKGROUND Glucagon-like peptide-1 (GLP-1) has been reported to exert some beneficial effects on the central nervous system (CNS). However, the effect of GLP-1 on cognitive impairment associated with type 2 diabetes is not well known. This study investigated the effect of GLP-1 on ameliorating memory deficits in type 2 diabetic rats. MATERIAL AND METHODS Type 2 diabetic rats were induced by a high-sugar, high-fat diet, followed by streptozotocin (STZ) injection and then tested in the Morris Water Maze (MWM) 1 week after the induction of diabetes. The mRNA expression of Arc, APP, BACE1, and PS1 were determined by real-time quantitative PCR, and the Arc protein was analyzed by immunoblotting and immunohistochemistry. RESULTS Type 2 diabetic rats exhibited a significant decline in learning and memory in the MWM tests, but GLP-1 treatment was able to protect this decline and significantly improved learning ability and memory. The mRNA expression assays showed that GLP-1 treatment markedly reduced Arc, APP, BACE1, and PS1 expressions, which were elevated in the diabetic rats. Immunoblotting and immunohistochemistry results also confirmed that Arc protein increased in the hippocampus of diabetic rats, but was reduced after GLP-1 treatment. CONCLUSIONS Our findings suggest that GLP-1 treatment improves learning and memory deficits in type 2 diabetic rats, and this effect is likely through the reduction of Arc expression in the hippocampus.</abstract><cop>United States</cop><pub>International Scientific Literature, Inc</pub><pmid>28885995</pmid><doi>10.12659/MSM.903252</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1643-3750
ispartof Medical science monitor, 2017-09, Vol.23, p.4334-4342
issn 1643-3750
1234-1010
1643-3750
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5601394
source PMC (PubMed Central)
subjects Animal Study
Animals
Blood Glucose - metabolism
Cognitive Dysfunction - blood
Cognitive Dysfunction - drug therapy
Cognitive Dysfunction - metabolism
Cytoskeletal Proteins - metabolism
Diabetes Mellitus, Experimental - metabolism
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - metabolism
Diet, High-Fat - adverse effects
Disease Models, Animal
Glucagon-Like Peptide 1 - pharmacology
Hippocampus - drug effects
Male
Maze Learning - drug effects
Memory Disorders - complications
Nerve Tissue Proteins - metabolism
Rats
Rats, Sprague-Dawley
title Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T22%3A12%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glucagon-Like%20Peptide-1%20(GLP-1)%20Treatment%20Ameliorates%20Cognitive%20Impairment%20by%20Attenuating%20Arc%20Expression%20in%20Type%202%20Diabetic%20Rats&rft.jtitle=Medical%20science%20monitor&rft.au=Cai,%20Xiang-Sheng&rft.date=2017-09-08&rft.volume=23&rft.spage=4334&rft.epage=4342&rft.pages=4334-4342&rft.issn=1643-3750&rft.eissn=1643-3750&rft_id=info:doi/10.12659/MSM.903252&rft_dat=%3Cproquest_pubme%3E1937528807%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2962-6a90a60b75f8925c46768cf1396380f4fd8f38c18b8ffccfe64c7afded34f9333%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1937528807&rft_id=info:pmid/28885995&rfr_iscdi=true